JP Morgan Call 190 CHKP 19.07.202.../ DE000JK0E8Y3 /
| 5/20/2024 9:06:31 AM | Chg.-0.001 | Bid10:00:37 PM | Ask10:00:37 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.002EUR | -33.33% | - Bid Size: - |
- Ask Size: - |
Check Point Software... | 190.00 USD | 7/19/2024 | Call |
GlobeNewswire
5/20
DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire
5/20
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
5/20
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire
5/20
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Adva...
GlobeNewswire
5/20
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)...
GlobeNewswire
5/18
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Co...
GlobeNewswire
5/17
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hir...
GlobeNewswire
5/15
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
5/15
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
5/15
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VIS...
GlobeNewswire
5/15
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Agains...
GlobeNewswire
5/15
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoin...
GlobeNewswire
5/15
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
5/15
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
5/15
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel ...
GlobeNewswire
5/14
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 f...
GlobeNewswire
5/14
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-17215...
GlobeNewswire
5/14
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
GlobeNewswire
5/14
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. ...
GlobeNewswire
5/13
DEADLINE ALERT for AVXL, HRT, and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class ...
GlobeNewswire
5/13
DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire
5/13
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
